Top 5 Cross-Border Life Sciences IP Licensing Risks—and How ADR Can Help Resolve Them

Cross-border collaborations in the life sciences—spanning pharmaceuticals, medical devices, diagnostics, and digital health—depend on complex IP licensing arrangements. Even well-drafted agreements, however, can be destabilized by differing legal regimes, discovery standards, procedural norms, and enforcement mechanisms across jurisdictions. These challenges create material legal and business risk that can threaten innovation, timelines, and commercial value.

This CLE program examines five recurring risks that arise in cross-border life sciences IP licensing and explores how alternative dispute resolution (ADR), including mediation and arbitration, can help manage and mitigate those risks. Participants will gain practical insight into structuring dispute resolution mechanisms that promote efficiency, neutrality, confidentiality, and enforceability, while aligning legal strategy with business objectives in a global regulatory environment.

JAMS neutrals Steven M. Bauer, Esq., FCIArb and Hon. Gregory M. Sleet (Ret.) will be the presenters on this complimentary CLE program.

Date: Tuesday, May 12, 2026

Time: 12:00pm - 2:30pm ET

Location: Capers & Lemons, 301 Little Falls Dr, Wilmington, DE 19808

1.5 General CLE Credits (DE) / Open to ACC GP Members